Robert Potashnick - 12 Feb 2026 Form 4 Insider Report for Envoy Medical, Inc. (COCH)

Role
Interim CFO
Signature
/s/ Andrew Nick as Attorney-in-Fact for Robert Potashnick pursuant to Power of Attorney filed herewith.
Issuer symbol
COCH
Transactions as of
12 Feb 2026
Net transactions value
+$85,000
Form type
4
Filing time
17 Feb 2026, 16:49:33 UTC
Previous filing
09 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Potashnick Robert Interim CFO C/O 4875 WHITE BEAR PARKWAY, WHITE BEAR LAKE /s/ Andrew Nick as Attorney-in-Fact for Robert Potashnick pursuant to Power of Attorney filed herewith. 16 Feb 2026 0001939454

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction COCH Class A Common Stock Purchase $85,000 +212,500 $0.4000 212,500 12 Feb 2026 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction COCH Warrant (right to buy) Purchase $0 +127,500 $0.000000 127,500 12 Feb 2026 Class A Common Stock 127,500 $0.4000 Direct F2, F3
transaction COCH Warrant (right to buy) Purchase $0 +212,500 $0.000000 212,500 12 Feb 2026 Class A Common Stock 212,500 $0.4000 Direct F2, F4
holding COCH Stock Option (right to buy) 15,000 12 Feb 2026 Class A Common Stock 15,000 $0.5300 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Options to purchase 3,750 shares vest on 2/5/2027, and 11,250 shares vest pro rata on the 5th of each month thereafter for 36 consecutive months.
F2 Exercisable upon shareholder approval of the issuance of shares of Class A Common Stock underlying the warrants.
F3 The Series A-1 Warrants expire on the earlier of (i) two years from the initial exercise date and (ii) 30 days after the date on which the Company announces that it has submitted a Premarket Approval Application to the Food and Drug Administration (FDA) for its Acclaim CI Device.
F4 The Series A-2 Warrants expire on the earlier of (i) five years from the initial exercise date and (ii) 30 days after the date on which the Company announces that it has received FDA approval for its Acclaim CI Device.